US drug regulator faces Trump heat
Down To Earth|January 16, 2025
FAILED REPUBLICAN presidential candidate Vivek Ramaswamy is making more news now than during his doomed attempt to get the party nomination for president. Ramaswamy's decision to throw in the towel and back Donald Trump after his campaign went nowhere showed acumen, the kind he is famous for in the investment world.
US drug regulator faces Trump heat

The president-elect has appointed the Indianorigin pharma investor, along with Elon Musk, as the head of an initiative to slash the federal bureaucracy. For Ramaswamy, heading the Department of Government Efficiency (DOGE) is the perfect reward: he does not like federal agencies and wants to shut down the Department of Education and the Federal Bureau of Investigation, and drastically restructure the Federal Reserve. But his main target is the Food and Drug Administration (FDA), the federal pharmaceutical regulator which has been in his cross hairs since the time he set up his drug manufacturing company Roivant Sciences and its much hyped drug failed to make the cut.

The story of Ramaswamy and his visceral antipathy to FDA is tied up with his business approach to pharma manufacture. He is given to projecting himself as a scientist from the biotechnology sphere, although he is no scientist, and has just an undergraduate degree in biology.

His graduate degree is in law and he started his career with a hedge fund company where he specialised in biotech investments. That appears to have fuelled the idea of setting up his own pharma ventures. His model was simple: scour the patent web for drugs that had been abandoned by pharma majors, buy out the patents-these could be had for a song-and develop and bring them to market to make a killing. The model was very much that of Martin Shkreli's, which we wrote about five years ago (see 'Encouraging orphan drugs', Down To Earth, November 1-15, 2019).

Shkreli was also a hedge fund manager who co-founded drug companies Retrophin and Turing Pharmaceuticals and became notorious for his rapacious pricing of pyrimethamine, a drug to treat parasitic infections. Shkreli had bought the rights to the drug at a throwaway price and hiked its price by 5,000 per cent.

This story is from the January 16, 2025 edition of Down To Earth.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the January 16, 2025 edition of Down To Earth.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM DOWN TO EARTHView All
THE CIRCULARITY ARGUMENT
Down To Earth

THE CIRCULARITY ARGUMENT

A circular economy can help India achieve its developmental aspirations while following the low-carbon pathway. It will also help address the challenges of waste management, pollution and overexploitation of natural resources. Industries are already innovating to reuse high-volume wastes and have shown that the transition can usher in both environmental and financial windfalls

time-read
10+ mins  |
February 01, 2025
Banking on flawed drug voluntary licences
Down To Earth

Banking on flawed drug voluntary licences

The Medicines Patent Pool is pushing for more VLs, but its bad deal with Novartis on a cancer drug shows the pitfalls

time-read
4 mins  |
February 01, 2025
Lasting solutions
Down To Earth

Lasting solutions

For the first time, the UN has recognised the role of indigenous communities in tackling aridity. A repository of traditional knowledge India has the wherewithal to lead the way

time-read
3 mins  |
February 01, 2025
IMD at 150
Down To Earth

IMD at 150

India's journey into modern weather forecasting took a decisive turn 150 years ago with the establishment of India Meteorological Department during the British rule. The agency has come a long way since then, shaping the way the country predicts and responds to its diverse climate challenges

time-read
2 mins  |
February 01, 2025
Every drop counts
Down To Earth

Every drop counts

In drought-prone Marathwada region, 14 villages have managed to counter water shortage by budgeting the resource

time-read
5 mins  |
February 01, 2025
Threat to survival
Down To Earth

Threat to survival

Hollongapar Gibbon Sanctuary in Assam faces ecological challenges as railway electrification and hydrocarbon exploration endanger its fragile biodiversity

time-read
5 mins  |
February 01, 2025
'Migration is going to be a battlefield'
Down To Earth

'Migration is going to be a battlefield'

AMITAV GHOSH is one of the foremost chroniclers of our times. His literary sojourn includes writings on topics that range from languages to climate change to human lives. His latest book, Wild Fictions, brings some of his works on these issues under one title. In a conversation with RAJAT GHAI, Ghosh shares his views on the future of human movement. Excerpts:

time-read
7 mins  |
February 01, 2025
Face of future
Down To Earth

Face of future

California wildfires confirm forest fires are intensifying in a hotter world, emitting substantial amounts of greenhouse gases and reinforcing global warming

time-read
6 mins  |
February 01, 2025
Friends of the forest
Down To Earth

Friends of the forest

Residents of 30 villages in Uttarakhand establish a model for public participation in saving forests from wildfires

time-read
2 mins  |
February 01, 2025
Climate-crazy playbook
Down To Earth

Climate-crazy playbook

Just hours after his second (and final) term began on January 20, US President Donald Trump unleashed 46 presidential actions. Several of these are centred on the US' climate commitments, energy transition, migration and trade policies, and are likely to have negative global implications

time-read
2 mins  |
February 01, 2025